Get startedLog in
    Picture of Immunoprecise Antibodies logo

    IPA — Immunoprecise Antibodies Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Immunoprecise Antibodies, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.

    2020
    April 30th
    2021
    April 30th
    2022
    April 30th
    2023
    April 30th
    2024
    April 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue14.117.919.420.724.5
    Cost of Revenue
    Gross Profit8.0311.51111.612.1
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Operating Interest Expense / Income
    Unusual Expense / Income
    Total Operating Expenses19.5233649.253.7
    Operating Profit-5.4-5.08-16.7-28.6-29.1
    Total Net Non Operating Interest Income / Expense
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-5.29-6-15.8-27.8-28.7
    Provision for Income Taxes
    Net Income After Taxes-4.95-7.34-16.7-26.6-27.2
    Net Income Before Extraordinary Items
    Net Income-4.95-7.34-16.7-26.6-27.2
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-4.95-7.34-16.7-26.6-27.2
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.323-0.545-0.846-1.07-0.679